Quest Diagnostics said net revenues for the 3-month period ended September 30, 2026 increased 10.0% from the prior-year period, with DIS revenues up 10.2%, DIS volume up 14.5%, and revenue per requisition down 4.2%.

1. 01

   Quest Diagnostics said net revenues for the 3-month period ended September 30, 2026 increased 10.0% from the prior-year period, with DIS revenues up 10.2%, DIS volume up 14.5%, and revenue per requisition down 4.2%.

2. 02

   The company said that of the DIS volume increase for Q3, 9.5% came from its new relationships with Corewell Health and Fresenius Medical Care. Excluding those, it said volume rose 5% and revenue per requisition rose 1.7%.

3. 03

   Quest Diagnostics said that in May 2026 it issued $500 million of 2036 senior notes at 5.00% at an issue discount of $6 million. It said that on June 1, 2026, it used the net proceeds and cash on hand to repay in full at maturity $500 million of its 3.45% senior notes.

4. 04

   The company said net cash provided by operating activities for the 9-month period ended September 30, 2026 was $1.5 billion ($1.4 billion in the prior-year period). It also said it repurchased 1.2 million shares for $250 million in the same period and that $1.2 billion remained under its repurchase authorization.

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.